The potential role of Th17 lymphocytes in patients with psoriasis

Abstract

BackgroundPsoriasis is a chronic inflammatory disorder, characterized by increased keratinocyte proliferation due to abnormal differentiation of basal keratinocytes. The etiology of the disease is unclear, and according to the survey results, it is hypothesized that a combination of genetic and environmental factors prompts an abnormal immune response in patients with psoriasis. CD4+ Th cells play a multifaceted role in both immune defense and pathogenesis of certain diseases such as psoriasis. Nonetheless, the exact contribution of different subpopulations of Th cells in psoriasis is still not clear. ObjectiveThe aim of present study was to determine the mRNA expression level of RORC as potential inducer of Th17 cell differentiation and expression pattern of Th17-signature cytokines (IL-17A and IL-22).MethodsTwenty patients with psoriasis and twenty-one healthy subjects were included in the study. Peripheral blood mononuclear cells (PBMCs) were separated and expression of three genes were determined by quantitative real-time reverse transcriptase PCR (qRT-PCR). Plasma levels of IL-17 and IL-22 were also evaluated by ELISA.ResultsRORC, IL-17A and IL-22 gene expression was significantly higher in patients with psoriasis compared with healthy controls (P<0.05). In addition, a marked increase in plasma IL-17A and IL-22 levels was observed in patient group compared to controls (P<0.001).Study limitationssmall number of patients.ConclusionThese data suggest that Th17 response may contribute to the pathogenesis of psoriasis.

Circulating CD14+HLA‐DR−/low Myeloid‐Derived Suppressor Cells as Potential Biomarkers for the Identification of Psoriasis TCM Blood‐Heat Syndrome and Blood‐Stasis Syndrome

“…Another possibility is that Mo-MDSCs downregulate IL-17A levels in circulation [31]. e transcription factor ROR-c plays a critical role in the expression of proinflammatory cytokine IL-17 in patients with psoriasis [32] and is, therefore, an attractive target for the treatment of psoriasis [33]. In the current study, we found the ROR-c mRNA levels were significantly increased in the PBMCs of psoriasis patients when compared to controls.…”

Secukinumab versus ustekinumab for skin clearance in patients with moderate to severe psoriasis after a year of treatment: Real‐world practice

“…Data from skin inflammatory models suggest that the Th17 lymphocytes, which produce cytokines IL‐17 and IL‐22, may be the main inducers of the epidermal hyperplasia associated with psoriasis. Cytokines IL‐12 and IL‐23 may also play a significant pathological role in this disease (Mansouri, Mansouri, Raze, & Jadali, ).…”

Polymorphism of Cytokine Genes (Il17a and Il17f) in Psoriasis and Psoriatic Arthritis

“…Полиморфизм IL17А (rs2275913) довольно активно изучается в отношении ассоциаций развития воспалительных мультифакториальных заболеваний. Так, в некоторых исследованиях не было получено ассоциации IL17А (rs2275913) с ПС и ПсА у поляков [25], а также с другим заболеванием суставов -ревматоидным артритом (РА) у тунисцев, алжирцев, поляков, бразильцев и китайцев [23,27]. В то же время, в других исследованиях показана ассоциация указанного полиморфизма с повышенным риском развития РА у бразильцев и норвежцев [28].…”

“…Ранее была показана ассоциация полиморфизма IL17F (rs763780) с ревматоидным артритом у европеоидов и связанная с этим повышенная концентрация IL-17 в сыворотке крови [23]. В польской популяции не найдена ассоциация IL17F (rs763780) с ПС и ПсА [25].…”

“…Функциональные полиморфизмы IL17A и IL17F изучаются также в отношении восприимчивости больных к терапии. Так, при локальном лечении больных ПС с применением ПУВА-терапии (NB-UVB) была продемонстрирована ее эффективность (оценивали по уменьшению индекса PASI) [25].…”